MARKET

IPHA

IPHA

Innate Pharma Sa
NASDAQ
1.410
-0.040
-2.76%
Closed 16:00 04/10 EDT
OPEN
1.420
PREV CLOSE
1.450
HIGH
1.450
LOW
1.410
VOLUME
46.33K
TURNOVER
--
52 WEEK HIGH
2.630
52 WEEK LOW
1.170
MARKET CAP
132.14M
P/E (TTM)
-2.1888
1D
5D
1M
3M
1Y
5Y
1D
Innate Pharma says Novo Nordisk stake falls to 4.9% of shares, 4.9% voting rights
Reuters · 3d ago
Innate Pharma to present at AACR oncology partnering event
Reuters · 4d ago
Innate Pharma Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
Dow Jones · 5d ago
HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $5 Price Target
Benzinga · 5d ago
Innate Pharma: Underappreciated Topo‑I ADC Pipeline and Differentiated IPH4502 Support Buy Rating
TipRanks · 5d ago
Weekly Report: what happened at IPHA last week (0330-0403)?
Weekly Report · 6d ago
Innate Pharma participates in Kempen Life Sciences Conference investor meetings
Reuters · 04/03 05:00
Innate Pharma to Participate in the Kempen Life Sciences Conference
Barchart · 04/03 00:00
More
About IPHA
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.

Webull offers Innate Pharma SA (ADR) stock information, including NASDAQ: IPHA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IPHA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IPHA stock methods without spending real money on the virtual paper trading platform.